CEPHALEXIN MONOHYDRATE CAPSULES,USP, 500 mg, 20-count bottle, Rx only, Manufactured for Caraco Ph...
FDA Drug Recall #D-0237-2015 — Class II — September 22, 2014
Recall Summary
| Recall Number | D-0237-2015 |
| Classification | Class II — Moderate risk |
| Date Initiated | September 22, 2014 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Physicians Total Care, Inc. |
| Location | Tulsa, OK |
| Product Type | Drugs |
| Quantity | 340 capsules (17 bottles containing 20 capsules each) |
Product Description
CEPHALEXIN MONOHYDRATE CAPSULES,USP, 500 mg, 20-count bottle, Rx only, Manufactured for Caraco Pharmaceuticals, Detroit, MI 48202 by Sun Pharmaceuticals, Fort Worth, TX 76155 and repackaged by Physicians Total Care, Inc., Tulsa, OK 74146-6233
Reason for Recall
CGMP deviations: Products were manufactured with active pharmaceutical ingredients that were not manufactured with good manufacturing practices.
Distribution Pattern
Distributed in Georgia and Missouri.
Lot / Code Information
Lot Code: 79MI (Exp. Date 01/31/2015), 79SF (Exp. Date 01/31/2015), 7AH5 (Exp. Date 06/30/2015)
Other Recalls from Physicians Total Care, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-390-2014 | Class II | Carisoprodol IV ( Carisoprodol Tablets USP) 350... | Nov 22, 2013 |
| D-0239-2015 | Class III | Loratadine 24 HR-OTC,10 mg, 30-count bottle, Ma... | Sep 11, 2013 |
| D-826-2013 | Class II | Belladonna Alkaloids/PB (Belladonna Alkaloids /... | Jun 17, 2013 |
| D-499-2013 | Class III | Camila 0.35 mg Tablets, 6 cards of 28 pills, Di... | Mar 18, 2013 |
| D-596-2013 | Class III | Voltaren 1% Gel, 100 gm tube, Rx only, Dist By:... | Mar 2, 2013 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.